Verrica Pharmaceuticals Inc. Accretion Expense
Verrica Pharmaceuticals Inc. (VRCA) reported Accretion Expense of $375.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2025-11-14
- 2025-09-30: Accretion Expense 9 month $375.00K.
- 2024-09-30: Accretion Expense 9 month $0.00.
| Period end | Accretion Expense 9 month |
|---|---|
| 2025-09-30 | $375.00K 10-Q · filed 2025-11-14 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |